Core Viewpoint - The company demonstrates strong confidence in its future development prospects, as evidenced by significant share purchases by concerted action members and a share buyback plan [1][2] Group 1: Share Purchases - Concerted action members have collectively purchased 11.05865 million shares at a total cost of approximately 96.34 million HKD since July 16, 2025 [1] - As of the announcement date, these members hold about 200.2 million shares, representing 25.28% of the company's total issued shares [1] - The members express confidence in the company's overall development prospects, growth potential, and long-term investment value [1] Group 2: Share Buyback Plan - The board has approved a share buyback plan not exceeding 100 million HKD, believing that the current share price does not reflect the company's actual value [1] - Since July 15, 2025, the company has repurchased a total of 326,400 shares, with a cumulative payment of 2.67 million HKD [1] - The company will continue to monitor market conditions and may exercise shareholder authorization for further share repurchases [1] Group 3: Business Operations and Product Pipeline - The board believes that the company's current business operations are in good condition, with encouraging progress in the development of core product pipelines, including but not limited to Pan-KRAS inhibitors [2] - The management's substantial share purchases and the company's share buyback actions reflect a strong confidence in the company's fundamentals and long-term growth prospects [2]
加科思-B(01167.HK)一致行动人增持股份至25.28% 公司同步实施回购